Pioglitazone and bladder cancer: a propensity score matched cohort study
WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT • Pioglitazone is mainly used in combination with diet and exercise and other anti‐diabetic medications to treat type 2 diabetes mellitus. • Long term use of pioglitazone (>24 months of therapy) may be associated with an increased risk of bladder cancer. W...
Saved in:
| Published in: | British journal of clinical pharmacology Vol. 75; no. 1; pp. 254 - 259 |
|---|---|
| Main Authors: | , , |
| Format: | Journal Article |
| Language: | English |
| Published: |
Oxford, UK
Blackwell Publishing Ltd
01.01.2013
Blackwell Science Inc |
| Subjects: | |
| ISSN: | 0306-5251, 1365-2125, 1365-2125 |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Abstract | WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT
• Pioglitazone is mainly used in combination with diet and exercise and other anti‐diabetic medications to treat type 2 diabetes mellitus.
• Long term use of pioglitazone (>24 months of therapy) may be associated with an increased risk of bladder cancer.
WHAT THIS STUDY ADDS
• In this study population, pioglitazone does not appear to be significantly associated with an increased risk of bladder cancer in patients with type 2 diabetes.
AIM To examine whether exposure to pioglitazone use is associated with increased incidence of bladder cancer in patients with type 2 diabetes mellitus.
METHOD A cohort study was done in the General Practice Research Database (GPRD) between 2001 and 2010. Two hundred and seven thousand seven hundred and fourteen patients aged ≥40 years with type 2 diabetes were studied (23 548 exposed to pioglitazone and 184 166 exposed to other antidiabetic medications but not pioglitazone). The association between pioglitazone and risk of bladder cancer was assessed by a Cox regression model. A propensity score matched analysis was done in a group of patients without missing baseline characteristics data.
RESULTS Sixty‐six and 803 new cases of bladder cancer occurred in the pioglitazone and other group, respectively (rates of 80.2 (95% CI 60.8, 99.5) and 81.8 (95% CI 76.2, 87.5) per 100 000 person‐years respectively). Pioglitazone did not increase the risk of bladder cancer significantly compared with the other antidiabetic drugs treatment group, (adjusted hazard ratio (HR), 1.16, 95% CI 0.83, 1.62). In a matched propensity score analysis in which both groups had similar baseline characteristics (17 249 patients in each group), the adjusted HR was 1.22 (95% CI 0.80, 1.84).
CONCLUSION The results suggest that pioglitazone may not be significantly associated with an increased risk of bladder cancer in patients with type 2 diabetes. |
|---|---|
| AbstractList | To examine whether exposure to pioglitazone use is associated with increased incidence of bladder cancer in patients with type 2 diabetes mellitus.
A cohort study was done in the General Practice Research Database (GPRD) between 2001 and 2010. Two hundred and seven thousand seven hundred and fourteen patients aged ≥40 years with type 2 diabetes were studied (23,548 exposed to pioglitazone and 184,166 exposed to other antidiabetic medications but not pioglitazone). The association between pioglitazone and risk of bladder cancer was assessed by a Cox regression model. A propensity score matched analysis was done in a group of patients without missing baseline characteristics data.
Sixty-six and 803 new cases of bladder cancer occurred in the pioglitazone and other group, respectively (rates of 80.2 (95% CI 60.8, 99.5) and 81.8 (95% CI 76.2, 87.5) per 100,000 person-years respectively). Pioglitazone did not increase the risk of bladder cancer significantly compared with the other antidiabetic drugs treatment group, (adjusted hazard ratio (HR), 1.16, 95% CI 0.83, 1.62). In a matched propensity score analysis in which both groups had similar baseline characteristics (17,249 patients in each group), the adjusted HR was 1.22 (95% CI 0.80, 1.84).
The results suggest that pioglitazone may not be significantly associated with an increased risk of bladder cancer in patients with type 2 diabetes. WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT • Pioglitazone is mainly used in combination with diet and exercise and other anti‐diabetic medications to treat type 2 diabetes mellitus. • Long term use of pioglitazone (>24 months of therapy) may be associated with an increased risk of bladder cancer. WHAT THIS STUDY ADDS • In this study population, pioglitazone does not appear to be significantly associated with an increased risk of bladder cancer in patients with type 2 diabetes. AIM To examine whether exposure to pioglitazone use is associated with increased incidence of bladder cancer in patients with type 2 diabetes mellitus. METHOD A cohort study was done in the General Practice Research Database (GPRD) between 2001 and 2010. Two hundred and seven thousand seven hundred and fourteen patients aged ≥40 years with type 2 diabetes were studied (23 548 exposed to pioglitazone and 184 166 exposed to other antidiabetic medications but not pioglitazone). The association between pioglitazone and risk of bladder cancer was assessed by a Cox regression model. A propensity score matched analysis was done in a group of patients without missing baseline characteristics data. RESULTS Sixty‐six and 803 new cases of bladder cancer occurred in the pioglitazone and other group, respectively (rates of 80.2 (95% CI 60.8, 99.5) and 81.8 (95% CI 76.2, 87.5) per 100 000 person‐years respectively). Pioglitazone did not increase the risk of bladder cancer significantly compared with the other antidiabetic drugs treatment group, (adjusted hazard ratio (HR), 1.16, 95% CI 0.83, 1.62). In a matched propensity score analysis in which both groups had similar baseline characteristics (17 249 patients in each group), the adjusted HR was 1.22 (95% CI 0.80, 1.84). CONCLUSION The results suggest that pioglitazone may not be significantly associated with an increased risk of bladder cancer in patients with type 2 diabetes. To examine whether exposure to pioglitazone use is associated with increased incidence of bladder cancer in patients with type 2 diabetes mellitus.AIMTo examine whether exposure to pioglitazone use is associated with increased incidence of bladder cancer in patients with type 2 diabetes mellitus.A cohort study was done in the General Practice Research Database (GPRD) between 2001 and 2010. Two hundred and seven thousand seven hundred and fourteen patients aged ≥40 years with type 2 diabetes were studied (23,548 exposed to pioglitazone and 184,166 exposed to other antidiabetic medications but not pioglitazone). The association between pioglitazone and risk of bladder cancer was assessed by a Cox regression model. A propensity score matched analysis was done in a group of patients without missing baseline characteristics data.METHODA cohort study was done in the General Practice Research Database (GPRD) between 2001 and 2010. Two hundred and seven thousand seven hundred and fourteen patients aged ≥40 years with type 2 diabetes were studied (23,548 exposed to pioglitazone and 184,166 exposed to other antidiabetic medications but not pioglitazone). The association between pioglitazone and risk of bladder cancer was assessed by a Cox regression model. A propensity score matched analysis was done in a group of patients without missing baseline characteristics data.Sixty-six and 803 new cases of bladder cancer occurred in the pioglitazone and other group, respectively (rates of 80.2 (95% CI 60.8, 99.5) and 81.8 (95% CI 76.2, 87.5) per 100,000 person-years respectively). Pioglitazone did not increase the risk of bladder cancer significantly compared with the other antidiabetic drugs treatment group, (adjusted hazard ratio (HR), 1.16, 95% CI 0.83, 1.62). In a matched propensity score analysis in which both groups had similar baseline characteristics (17,249 patients in each group), the adjusted HR was 1.22 (95% CI 0.80, 1.84).RESULTSSixty-six and 803 new cases of bladder cancer occurred in the pioglitazone and other group, respectively (rates of 80.2 (95% CI 60.8, 99.5) and 81.8 (95% CI 76.2, 87.5) per 100,000 person-years respectively). Pioglitazone did not increase the risk of bladder cancer significantly compared with the other antidiabetic drugs treatment group, (adjusted hazard ratio (HR), 1.16, 95% CI 0.83, 1.62). In a matched propensity score analysis in which both groups had similar baseline characteristics (17,249 patients in each group), the adjusted HR was 1.22 (95% CI 0.80, 1.84).The results suggest that pioglitazone may not be significantly associated with an increased risk of bladder cancer in patients with type 2 diabetes.CONCLUSIONThe results suggest that pioglitazone may not be significantly associated with an increased risk of bladder cancer in patients with type 2 diabetes. WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT • Pioglitazone is mainly used in combination with diet and exercise and other anti‐diabetic medications to treat type 2 diabetes mellitus. • Long term use of pioglitazone (>24 months of therapy) may be associated with an increased risk of bladder cancer. WHAT THIS STUDY ADDS • In this study population, pioglitazone does not appear to be significantly associated with an increased risk of bladder cancer in patients with type 2 diabetes. AIM To examine whether exposure to pioglitazone use is associated with increased incidence of bladder cancer in patients with type 2 diabetes mellitus. METHOD A cohort study was done in the General Practice Research Database (GPRD) between 2001 and 2010. Two hundred and seven thousand seven hundred and fourteen patients aged ≥40 years with type 2 diabetes were studied (23 548 exposed to pioglitazone and 184 166 exposed to other antidiabetic medications but not pioglitazone). The association between pioglitazone and risk of bladder cancer was assessed by a Cox regression model. A propensity score matched analysis was done in a group of patients without missing baseline characteristics data. RESULTS Sixty‐six and 803 new cases of bladder cancer occurred in the pioglitazone and other group, respectively (rates of 80.2 (95% CI 60.8, 99.5) and 81.8 (95% CI 76.2, 87.5) per 100 000 person‐years respectively). Pioglitazone did not increase the risk of bladder cancer significantly compared with the other antidiabetic drugs treatment group, (adjusted hazard ratio (HR), 1.16, 95% CI 0.83, 1.62). In a matched propensity score analysis in which both groups had similar baseline characteristics (17 249 patients in each group), the adjusted HR was 1.22 (95% CI 0.80, 1.84). CONCLUSION The results suggest that pioglitazone may not be significantly associated with an increased risk of bladder cancer in patients with type 2 diabetes. |
| Author | MacDonald, Thomas M. Mackenzie, Isla S. Wei, Li |
| Author_xml | – sequence: 1 givenname: Li surname: Wei fullname: Wei, Li – sequence: 2 givenname: Thomas M. surname: MacDonald fullname: MacDonald, Thomas M. – sequence: 3 givenname: Isla S. surname: Mackenzie fullname: Mackenzie, Isla S. |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/22574756$$D View this record in MEDLINE/PubMed |
| BookMark | eNqNkU9PGzEQxS1EBeHPV0A-ctlgez2bLBJINCpNJaRy4D7y2rPE0WYd7E1L-um7Wwi0PeGLR5p5743md8T229ASY1yKsezfxXIs8wIyJRWMlZBqLHTel897bPTW2GcjkYsiAwXykB2ltBRC5rKAA3aoFEz0BIoRm9_78Nj4zvzqE7hpHa8a4xxFbk1rKV5yw9cxrKlNvtvyZEMkvjKdXZDjNixC7HjqNm57wj7Vpkl0-vofs4fbLw-zeXb3_eu32c1dZnUpIKvctNZq6nJbuMqBohocTAhUNRWuNrXWtRGlBaGA-nmlqXJFWRoQ0smS8mN2_WK73lQrcpbaLpoG19GvTNxiMB7_7bR-gY_hB-YAIAroDc5fDWJ42lDqcOWTpaYxLYVNQqm0UFJPdNGPnv2d9Rayu977MjaGlCLVaPtLdj4M0b5BKXDAhUscqOBABQdc-AcXPvcG0_8MdhkfkF69SH_6hrYf1uHn2f1Q5b8BdQ6tpA |
| CitedBy_id | crossref_primary_10_1089_dia_2012_0246 crossref_primary_10_1155_2019_2376512 crossref_primary_10_1007_s13300_017_0273_4 crossref_primary_10_1007_s13300_015_0128_9 crossref_primary_10_1016_j_clinthera_2019_08_018 crossref_primary_10_1634_theoncologist_2013_0216 crossref_primary_10_1152_physrev_00030_2014 crossref_primary_10_1111_dme_13854 crossref_primary_10_1517_13543784_2015_963195 crossref_primary_10_1586_17446651_2015_1054809 crossref_primary_10_1080_10408444_2017_1351420 crossref_primary_10_1111_jdi_14152 crossref_primary_10_2337_dcS13_2031 crossref_primary_10_1185_03007995_2014_941054 crossref_primary_10_1002_lrh2_10293 crossref_primary_10_1080_10590501_2014_877645 crossref_primary_10_1007_s00125_014_3456_9 crossref_primary_10_1016_j_jaci_2014_10_034 crossref_primary_10_1186_s12859_016_1080_z crossref_primary_10_1111_bcp_12306 crossref_primary_10_1097_CEJ_0000000000000195 crossref_primary_10_1111_dom_12180 crossref_primary_10_3390_ijerph192416518 crossref_primary_10_1007_s12325_012_0044_6 crossref_primary_10_1016_j_japh_2016_11_005 crossref_primary_10_1155_2014_719578 crossref_primary_10_1016_j_biocel_2016_08_011 crossref_primary_10_1038_s41598_017_16074_1 crossref_primary_10_1007_s13340_018_0360_4 crossref_primary_10_1080_14740338_2017_1361401 crossref_primary_10_1111_dme_12627 crossref_primary_10_1111_bcp_12145 crossref_primary_10_1186_s13098_015_0059_7 crossref_primary_10_1002_cam4_1354 crossref_primary_10_1111_bcp_12740 crossref_primary_10_1634_theoncologist_2012_0302 crossref_primary_10_1634_theoncologist_2013_0087 crossref_primary_10_1007_s11695_013_0930_2 crossref_primary_10_1111_dom_13049 crossref_primary_10_3390_cancers14235811 crossref_primary_10_1007_s40264_013_0086_y crossref_primary_10_1007_s00204_016_1737_4 crossref_primary_10_1007_s00125_014_3460_0 crossref_primary_10_1111_dom_12608 crossref_primary_10_1016_j_dsx_2022_102637 crossref_primary_10_1016_j_jdiacomp_2016_04_004 crossref_primary_10_4103_ijmr_IJMR_650_15 crossref_primary_10_1016_j_cegh_2017_08_002 crossref_primary_10_1016_j_prp_2014_06_003 crossref_primary_10_1152_physrev_00027_2013 crossref_primary_10_1016_j_diabres_2017_11_002 crossref_primary_10_1080_14740338_2024_2390000 crossref_primary_10_1007_s40801_019_0160_6 crossref_primary_10_1111_dom_13774 crossref_primary_10_1016_j_urology_2012_12_027 crossref_primary_10_1111_jdi_12068 crossref_primary_10_2337_dc14_2441 crossref_primary_10_1007_s00404_017_4480_z crossref_primary_10_1002_pds_3834 crossref_primary_10_1007_s40261_013_0106_9 |
| Cites_doi | 10.2105/AJPH.88.1.15 10.1136/bmj.317.7168.1309 10.2337/dc10-1068 10.1016/j.amjcard.2008.11.045 10.1001/jama.2011.939 10.1517/14740331003623218 |
| ContentType | Journal Article |
| Copyright | 2012 The Authors. British Journal of Clinical Pharmacology © 2012 The British Pharmacological Society 2012 The Authors. British Journal of Clinical Pharmacology © 2012 The British Pharmacological Society. Copyright © 2013 The British Pharmacological Society 2013 |
| Copyright_xml | – notice: 2012 The Authors. British Journal of Clinical Pharmacology © 2012 The British Pharmacological Society – notice: 2012 The Authors. British Journal of Clinical Pharmacology © 2012 The British Pharmacological Society. – notice: Copyright © 2013 The British Pharmacological Society 2013 |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 5PM |
| DOI | 10.1111/j.1365-2125.2012.04325.x |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic PubMed Central (Full Participant titles) |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic CrossRef |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Pharmacy, Therapeutics, & Pharmacology |
| EISSN | 1365-2125 |
| EndPage | 259 |
| ExternalDocumentID | PMC3555065 22574756 10_1111_j_1365_2125_2012_04325_x BCP4325 |
| Genre | article Journal Article |
| GrantInformation_xml | – fundername: Medical Research Council grantid: G106/1249 |
| GroupedDBID | --- .3N .55 .GA .GJ .Y3 05W 0R~ 10A 1OC 23N 2WC 31~ 33P 36B 3O- 3SF 4.4 50Y 50Z 51W 51X 52M 52N 52O 52P 52R 52S 52T 52U 52V 52W 52X 53G 5GY 5HH 5LA 5VS 66C 6J9 702 7PT 8-0 8-1 8-3 8-4 8-5 8UM 930 A01 A03 AAESR AAEVG AAHQN AAIPD AAMMB AAMNL AANLZ AAONW AASGY AAXRX AAYCA AAZKR ABCQN ABCUV ABEML ABOCM ABPVW ABQWH ABXGK ACAHQ ACCZN ACFBH ACGFO ACGFS ACGOF ACMXC ACPOU ACSCC ACXBN ACXQS ADBBV ADBTR ADEOM ADIZJ ADKYN ADMGS ADOZA ADXAS ADZMN AEFGJ AEGXH AEIGN AEIMD AENEX AEUYR AEYWJ AFBPY AFEBI AFFPM AFGKR AFWVQ AFZJQ AGHNM AGXDD AGYGG AHBTC AIACR AIAGR AIDQK AIDYY AITYG AIURR ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN ALVPJ AMBMR AMYDB AOIJS ATUGU AZBYB AZVAB BAFTC BAWUL BFHJK BHBCM BMXJE BROTX BRXPI BY8 C45 CAG COF CS3 D-6 D-7 D-E D-F DCZOG DIK DPXWK DR2 DRFUL DRMAN DRSTM DU5 E3Z EBS EJD EMOBN EX3 F00 F01 F04 F5P FUBAC G-S G.N GODZA GX1 H.X HF~ HGLYW HYE HZI HZ~ IHE IX1 J0M K48 KBYEO LATKE LC2 LC3 LEEKS LH4 LITHE LOXES LP6 LP7 LSO LUTES LW6 LYRES MEWTI MK4 MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM N04 N05 N9A NF~ O66 O9- OIG OK1 OVD P2P P2W P2X P2Z P4B P4D Q.N Q11 QB0 R.K ROL RX1 SUPJJ TEORI TR2 UB1 V8K W8V W99 WBKPD WHWMO WIH WIJ WIK WIN WOHZO WOW WQJ WVDHM WXI WXSBR X7M XG1 YFH YOC YUY ZGI ZXP ZZTAW ~IA ~WT AAYXX CITATION O8X CGR CUY CVF ECM EIF NPM 7X8 5PM |
| ID | FETCH-LOGICAL-c4905-bd8f428d3c6dbd52ef5d57e52b80dfaf44fa09c5025e90524ebd699a501d19e3 |
| IEDL.DBID | DRFUL |
| ISICitedReferencesCount | 74 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000312528100025&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 0306-5251 1365-2125 |
| IngestDate | Thu Aug 21 14:00:17 EDT 2025 Fri Jul 11 10:51:26 EDT 2025 Mon Jul 21 05:20:05 EDT 2025 Tue Nov 18 21:08:24 EST 2025 Sat Nov 29 03:44:53 EST 2025 Sun Sep 21 06:18:25 EDT 2025 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Language | English |
| License | http://onlinelibrary.wiley.com/termsAndConditions#vor 2012 The Authors. British Journal of Clinical Pharmacology © 2012 The British Pharmacological Society. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c4905-bd8f428d3c6dbd52ef5d57e52b80dfaf44fa09c5025e90524ebd699a501d19e3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| PMID | 22574756 |
| PQID | 1240214746 |
| PQPubID | 23479 |
| PageCount | 6 |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_3555065 proquest_miscellaneous_1240214746 pubmed_primary_22574756 crossref_citationtrail_10_1111_j_1365_2125_2012_04325_x crossref_primary_10_1111_j_1365_2125_2012_04325_x wiley_primary_10_1111_j_1365_2125_2012_04325_x_BCP4325 |
| PublicationCentury | 2000 |
| PublicationDate | January 2013 |
| PublicationDateYYYYMMDD | 2013-01-01 |
| PublicationDate_xml | – month: 01 year: 2013 text: January 2013 |
| PublicationDecade | 2010 |
| PublicationPlace | Oxford, UK |
| PublicationPlace_xml | – name: Oxford, UK – name: England |
| PublicationTitle | British journal of clinical pharmacology |
| PublicationTitleAlternate | Br J Clin Pharmacol |
| PublicationYear | 2013 |
| Publisher | Blackwell Publishing Ltd Blackwell Science Inc |
| Publisher_xml | – name: Blackwell Publishing Ltd – name: Blackwell Science Inc |
| References | 1998; 317 2011; 34 2011; 306 2012 2011 2009; 103 1998; 88 2010; 9 e_1_2_7_5_2 e_1_2_7_10_2 e_1_2_7_4_2 e_1_2_7_3_2 e_1_2_7_2_2 e_1_2_7_9_2 e_1_2_7_8_2 e_1_2_7_7_2 e_1_2_7_6_2 |
| References_xml | – year: 2011 – volume: 9 start-page: 347 year: 2010 end-page: 54 article-title: Pioglitazone: side effect and safety profile publication-title: Expert Opin Drug Saf – volume: 34 start-page: 916 year: 2011 end-page: 22 article-title: Risk of bladder cancer among diabetic patients treated with pioglitazone: interim report of a longitudinal cohort study publication-title: Diabetes Care – volume: 88 start-page: 15 year: 1998 end-page: 9 article-title: Use and misuse of population attributable fractions publication-title: Am J Public Health – volume: 317 start-page: 1309 year: 1998 end-page: 12 article-title: Confidence intervals for the number needed to treat publication-title: BMJ – volume: 306 start-page: 143 year: 2011 article-title: Diabetes drug may be associated with increase in risk of bladder cancer publication-title: JAMA – volume: 103 start-page: 839 year: 2009 end-page: 44 article-title: A propensity‐matched study of elevated jugular venous pressure and outcomes in chronic heart failure publication-title: Am J Cardiol – year: 2012 – ident: e_1_2_7_5_2 – ident: e_1_2_7_6_2 doi: 10.2105/AJPH.88.1.15 – ident: e_1_2_7_10_2 doi: 10.1136/bmj.317.7168.1309 – ident: e_1_2_7_2_2 doi: 10.2337/dc10-1068 – ident: e_1_2_7_4_2 doi: 10.1016/j.amjcard.2008.11.045 – ident: e_1_2_7_9_2 doi: 10.1001/jama.2011.939 – ident: e_1_2_7_3_2 – ident: e_1_2_7_8_2 – ident: e_1_2_7_7_2 doi: 10.1517/14740331003623218 |
| SSID | ssj0013165 |
| Score | 2.3725848 |
| Snippet | WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT
• Pioglitazone is mainly used in combination with diet and exercise and other anti‐diabetic medications to treat type... To examine whether exposure to pioglitazone use is associated with increased incidence of bladder cancer in patients with type 2 diabetes mellitus. A cohort... To examine whether exposure to pioglitazone use is associated with increased incidence of bladder cancer in patients with type 2 diabetes mellitus.AIMTo... |
| SourceID | pubmedcentral proquest pubmed crossref wiley |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 254 |
| SubjectTerms | Adult Aged bladder cancer Cohort Studies cohort study Diabetes Mellitus, Type 2 - drug therapy Drug Safety Female Humans Hypoglycemic Agents - adverse effects Male Middle Aged Pioglitazone Proportional Hazards Models Risk Thiazolidinediones - adverse effects Urinary Bladder Neoplasms - chemically induced |
| Title | Pioglitazone and bladder cancer: a propensity score matched cohort study |
| URI | https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fj.1365-2125.2012.04325.x https://www.ncbi.nlm.nih.gov/pubmed/22574756 https://www.proquest.com/docview/1240214746 https://pubmed.ncbi.nlm.nih.gov/PMC3555065 |
| Volume | 75 |
| WOSCitedRecordID | wos000312528100025&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVWIB databaseName: Wiley Online Library Free Content customDbUrl: eissn: 1365-2125 dateEnd: 20241207 omitProxy: false ssIdentifier: ssj0013165 issn: 0306-5251 databaseCode: WIN dateStart: 19970101 isFulltext: true titleUrlDefault: https://onlinelibrary.wiley.com providerName: Wiley-Blackwell – providerCode: PRVWIB databaseName: Wiley Online Library Full Collection 2020 customDbUrl: eissn: 1365-2125 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0013165 issn: 0306-5251 databaseCode: DRFUL dateStart: 19970101 isFulltext: true titleUrlDefault: https://onlinelibrary.wiley.com providerName: Wiley-Blackwell |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1La9wwEBbtpode-n5sH0GFklMc1rJkS721aZcUymLKlu5NSJaULgRvsDch6a_vjOzsxqSHUHqzsSTGoxnpkzT6hpD3GcDcUAWZBCOzhDObJUblNlFIJFLZTIaiSzZRzGZysVBlH_-Ed2E6fojNhht6Rhyv0cGNbYdOHiO0YIbGCC12gORy4gDw5A4DMxYjsvP5-_THt-2ZQhoTSyJIhuWXSIdxPX9tazhZ3UCgNwMprwPcOENNH_7Pf3tEHvQ4lX7sDOsxuePrJ2Sv7IiuL_fpfHtvq92ne7TcUmBfPiVH5XJ1jPTfv1e1p6Z21J7gENfQCq2s-UANPcVjgBpDQmiLXJoUsDNYkKOYs7dZ00h8-4zMp1_mh0dJn7MhqbiaiMQ6GWBF47Iqd9YJ5oNwovCCWTlxwQTOg5moSgDU8lCecW9drpQRk9SlymfPyagGyV4SyvDqivdcGSm5LQCJsuDywmbBOGtYPibFVd_oquczx7QaJ_rauga0qFGLGrWooxb1xZikm5qnHafHLeq8u-p-DQ6Ipyqm9quzVqd4PpXygoNELzpz2LQKgyUs1wTKOjCUTQEk9x5-qZe_Isk34EAB8HBM8mgotxZUfzos8enVv1Z8Te6zmPIDt5nekNG6OfNvyb3qfL1sm11yt1jI3d614O3n19kfaQEh5w |
| linkProvider | Wiley-Blackwell |
| linkToHtml | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3dS-QwEA-HHngvp97nnl8RxCcr2zRpG99UlBW9pQ8L-haSJvEWpCvdVfT-emfSddfiPcjhW6FNmE5mkl8yk98QspMAzPWlzyOv8yTizCSRlqmJJBKJlCbJfdYUm8j6_fzqShbTckB4F6bhh5gduKFnhPkaHRwPpNteHlK0YInGFC22j-xyYh8A5SIH3IF1HC7P-vOQQhzqSiJGht2XiNtpPf_sqb1WvQKgr_MoX-LbsECdLr_rr62Qz1OcSg8bw1olH1z1hewWDdH14x4dzO9tjffoLi3mFNiPX0mvGI6ukf7776hyVFeWmhuc4mpaopXVB1TTWwwDVJgSQsfIpUkBO4MFWYo1e-sJDcS338jg9GRw3IumNRuiksuuiIzNPexobFKm1ljBnBdWZE4wk3et155zr7uyFAC1HHzPuDM2lVKLbmxj6ZLvZKECyX4SyvDqinNc6jznJgMkyrxNM5N4bY1maYdkz4OjyimfOZbVuFEv9jWgRYVaVKhFFbSoHjoknrW8bTg93tBm-3n8FTggRlV05UZ3YxVjfCrmGQeJfjT2MOsVJkvYrgmUtWUpsw-Q3Lv9phr-CSTfgAMFwMMOSYOlvFlQdXRc4NOv_224RZZ6g98X6uKsf75GPrFQ_gOPnNbJwqS-cxvkY3k_GY7rzeBfT3_-IrI |
| linkToPdf | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3fa9swEBYlHWMvW7duXbZuU6H0qS6xLNnW3vpjoWMlmJJB34RkSW2gOMFJx7q_fneym9R0D2X0zWBLnE930nfS6TtCdhOAub70eeR1nkScmSTSMjWRRCKR0iS5z5piE9lolF9cyKItB4R3YRp-iOWGG3pGmK_Rwd3M-q6XhxQtWKIxRYsdILucOABAuc6xpkyPrJ-cD3-erQ4V4lBZElEyxF8i7ib2_LOv7mr1AII-zKS8j3DDEjV89aQ_t0FetkiVHjam9ZqsueoN2SsaquvbfTpe3dya79M9WqxIsG83yWkxmV4iAfifaeWoriw11zjJ1bREO6u_Uk1neBBQYVIInSObJgX0DDZkKVbtrRc0UN--JePht_HxadRWbYhKLgciMjb3ENPYpEytsYI5L6zInGAmH1ivPedeD2QpAGw5-J5xZ2wqpRaD2MbSJe9IrwLJ3hPK8PKKc1zqPOcmAyzKvE0zk3htjWZpn2R3g6PKltEcC2tcq3uRDWhRoRYValEFLarffRIvW84aVo9HtNm5G38FLojnKrpy05u5ivGEKuYZB4m2GntY9grTJQRsAmXtWMryA6T37r6pJleB5huQoACA2CdpsJRHC6qOjgt8-vC_Db-Q58XJUJ19H_34SF6wUP8D95y2SW9R37hP5Fn5azGZ159bB_sLei4jWw |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Pioglitazone+and+bladder+cancer%3A+a+propensity+score+matched+cohort+study&rft.jtitle=British+journal+of+clinical+pharmacology&rft.au=Wei%2C+Li&rft.au=MacDonald%2C+Thomas+M.&rft.au=Mackenzie%2C+Isla+S.&rft.date=2013-01-01&rft.pub=Blackwell+Publishing+Ltd&rft.issn=0306-5251&rft.eissn=1365-2125&rft.volume=75&rft.issue=1&rft.spage=254&rft.epage=259&rft_id=info:doi/10.1111%2Fj.1365-2125.2012.04325.x&rft.externalDBID=10.1111%252Fj.1365-2125.2012.04325.x&rft.externalDocID=BCP4325 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0306-5251&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0306-5251&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0306-5251&client=summon |